1 of 1
Story summary
- The U.S. Food and Drug Administration (FDA) issued draft guidance to simplify biosimilar development and lower drug costs.
- FDA Commissioner Marty Makary said the agency will use more precise analytical testing methods.
- The framework would allow data from non-U.S.-licensed products for approval and aligns with the Trump administration's broader drug pricing reforms.
